The initial Phase 1 data are encouraging with clear efficacy signals and manageable safety, supporting CLN-978's potential in autoimmune diseases. Watch the Immunology Day on June 10 for the RA multi-dose cohort and velinotamig data, which could further de-risk the platform. Interim data are early and subject to change with longer follow-up.
Price Chart
Executive Summary
Cullinan Therapeutics presented initial Phase 1 data for CLN-978 (CD19xCD3 T cell engager) in SLE and RA at EULAR 2026. In 29 patients, the drug showed clinical benefit including remissions, deep B cell depletion, and a manageable safety profile up to 30 µg target doses. The company also announced an Immunology Day on June 10 for additional data, including the first RA multi-dose cohort and initial velinotamig data.
Key Facts
- Initial Phase 1 data from 29 patients (18 SLE, 11 RA) as of May 15, 2026
- In SLE: 71% (10/14) achieved ≥4-point hSLEDAI reduction; 5 achieved DORIS remission
- In RA: 71% (5/7) showed disease activity improvement; 1 DAS28-ESR remission at 30 µg
- Peripheral B cell depletion >80% in 82% (14/17) of SLE patients; BLOQ in 50% at ≥20 µg
- BLOQ B cell depletion in 67% (4/6) of RA patients at ≥20 µg; tissue depletion also observed
- Safety: mostly Grade 1 CRS; one Grade 3 CRS at 45 µg (cohort discontinued); no ICANS
- Immunology Day on June 10 to present RA multi-dose data and initial velinotamig data
Financial Impact
No financial data provided; pre-revenue clinical-stage biotech. Positive early efficacy/safety data supports pipeline value.
Risk Factors
- Interim data from small sample (n=29); results may change with more patients and longer follow-up
- Grade 3 CRS at 45 µg led to cohort discontinuation; multi-dose safety not yet fully characterized
- No financial data in filing; pre-revenue biotech with no approved products
- Forward-looking statements only; no hard guidance or quantitative financial metrics
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-260640 |
| Document: cgem-20260606.htm | 0001193125-26-260640 |
| Document: 0001193125-26-260640-index-headers.html | 0001193125-26-260640 |
| Document: 0001193125-26-260640-index.html | 0001193125-26-260640 |
| Document: 0001193125-26-260640.txt | 0001193125-26-260640 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 1, 2026 24d ago | Press Release | $15.51 | awaiting T+60 | — | $14.54 (−6.25%) |
Sep 24, 2026 4w ago | 8-K | $15.44 | awaiting T+60 | — | $14.54 (−5.83%) |
Sep 24, 2026 4w ago | Press Release | $15.44 | awaiting T+60 | — | $14.54 (−5.83%) |
Sep 22, 2026 4w ago | Institutional Cluster | $21.67 | awaiting T+60 | — | $14.54 (−32.90%) |
Sep 14, 2026 6w ago | 8-K | $20.40 | awaiting T+60 | — | $14.54 (−28.73%) |
Aug 6, 2026 11w ago | 8-K | $17.95 | awaiting T+60 | — | $14.54 (−19.00%) |
Jun 11, 2026 19w ago | Institutional Cluster | $12.98 $21.69 | ▲ +67.10% | ▲ +63.28% | $14.54 (+12.02%) |
Jun 10, 2026 19w ago | Press Release | $12.05 $22.09 | ▲ +83.32% | ▲ +77.15% | $14.54 (+20.66%) |
Jun 8, 2026 20w ago | 8-K | $13.28 $22.33 | ▲ +68.15% | ▲ +64.64% | $14.54 (+9.49%) |
May 19, 2026 22w ago | Press Release | $14.18 $19.64 | ▲ +38.55% | ▲ +32.26% | $14.54 (+2.57%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers